Ironwood Pharmaceuticals
Ironwood Pharmaceuticals' revenue fell 15.7% to $296 million in fiscal 2025. Its operating margin was 33.3%, up from 26.5% a year earlier. Free cash flow was $127 million, up 22.8%. The diluted share count rose 1.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Ironwood Pharmaceuticals does
Ironwood Pharmaceuticals is a biotechnology company focused on digestive (gastrointestinal) and rare diseases. Its only commercial product is LINZESS (linaclotide), the first approved drug in a class of digestive medicines called GC-C agonists. In the U.S. it treats irritable bowel syndrome with constipation and chronic constipation in adults, and some constipation in children. It is also sold in Mexico, Japan and China, and as CONSTELLA in Canada and parts of Europe.
Ironwood does not sell linaclotide worldwide by itself. It has partners: AbbVie in the U.S. and most other countries, AstraZeneca in China and Astellas in Japan.
Its main drug in development is apraglutide, a long-acting injected peptide for short bowel syndrome patients who depend on intravenous nutrition. It came with the June 2023 purchase of VectivBio. In 2025 the FDA told Ironwood it needs a confirmatory Phase III trial, called STARS-2, before it can seek approval. Ironwood was incorporated in Delaware in 1998 as Microbia.
Its biggest risks, as it describes them
- Apraglutide may not win regulatory approval, and a further Phase III trial is needed first.
- Delays in clinical testing could raise costs and delay revenue.
- It depends on one commercial product, LINZESS, sold mostly through partners.
- The VectivBio purchase increases its exposure to doing business in foreign countries.
- It may be unable to keep the benefits of orphan drug designation, including market exclusivity.
Income statement
From fiscal 2019 to 2025, earnings per share grew 1.2% a year and net income 1.9% a year, as new shares raised the share count by 4% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 620 | 656 | 92 | 89 | 216 |
| Debt incl. finance leases | 454 | 396 | 398 | — | — |
| Net debt (negative means net cash) | −166 | −260 | 306 | — | — |
| Net debt to EBITDA | −0.7x | −1.0x | — | — | — |
| Debt to equity | 0.8x | 0.6x | — | — | — |
| Interest coverage | 7.5x | 33.0x | −43.7x | 2.8x | 3.0x |
| Current ratio | 4.6x | 30.6x | 0.8x | 4.7x | 1.1x |
| Quick ratio | 4.6x | 30.6x | 0.8x | 4.7x | 1.1x |
Cash flow
Projections
Project Ironwood Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Ironwood Pharmaceuticals reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 8 | — | — |
| Rule of 40 | 49.2% | 8.8% | 27.2% |
| Altman Z'' | −26.28 | −11.79 | −11.97 |
| Accruals ratio | −150.9% | −25.0% | −27.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 8 | — | — |
Compare
Put Ironwood Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals | FY25 | −15.7% | 33.3% | 42.9% | — | — | — | |
| Evolus | FY25 | 11.6% | −11.0% | −15.4% | −47.2% | — | 2 | Compare |
| Rigel Pharmaceuticals | FY25 | 64.2% | 42.6% | — | 91.3% | −0.8x | 7 | Compare |
| Xeris Biopharma | FY25 | 43.7% | 8.5% | — | 19.6% | 4.2x | 7 | Compare |
| Aurinia Pharmaceuticals | FY25 | 20.4% | 37.1% | 47.8% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 274 | 298 | 347 | 428 | 390 | 414 | 411 | 443 | 351 | 296 |
| Revenue growth | 83.2% | 8.9% | 16.2% | 23.6% | −9.1% | 6.2% | −0.8% | 7.8% | −20.6% | −15.7% |
| Gross profit | 272 | 279 | 314 | 404 | 386 | — | — | — | — | — |
| Research and development | 140 | 88 | 101 | 115 | 88 | 70 | 44 | 116 | 111 | 95 |
| Operating income | −52 | −15 | −151 | 120 | 143 | 232 | 250 | −945 | 93 | 98 |
| Net income | −82 | −117 | −282 | 22 | 106 | 528 | 175 | −1,002 | 1 | 24 |
| Diluted EPS (US$) | −0.56 | −0.78 | −1.85 | 0.14 | 0.66 | 3.21 | 0.96 | −6.45 | 0.01 | 0.15 |
| Diluted shares (millions) | 145 | 149 | 153 | 156 | 161 | 164 | 186 | 155 | 160 | 163 |
| Cash flow | ||||||||||
| Cash from operations | −26 | −101 | −71 | 11 | 169 | 262 | 274 | 183 | 104 | 127 |
| Capital expenditure | 4 | 3 | 0 | 7 | 2 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −30 | −104 | −71 | 4 | 167 | 262 | 274 | 183 | 103 | 127 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 24 | 126 | 0 | 0 | 0 |
| Acquisitions | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 29 | 31 | 40 | 31 | 31 | 22 | 27 | 32 | 30 | 17 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 54 | 221 | — | 177 | 363 | 620 | 656 | 92 | 89 | 216 |
| Debt incl. finance leases | — | 147 | 148 | — | 430 | 454 | 396 | 398 | — | — |
| Total assets | 710 | 606 | 332 | 403 | 559 | 1,127 | 1,100 | 471 | 351 | 397 |
| Total liabilities | 643 | 596 | 528 | 496 | 497 | 521 | 448 | 817 | 652 | 659 |
| Shareholders' equity | 67 | 10 | −196 | −93 | 63 | 606 | 652 | −346 | −301 | −262 |
| Margins and ratios | ||||||||||
| Gross margin | 99.3% | 93.6% | 90.5% | 94.4% | 99.2% | — | — | — | — | — |
| Operating margin | −18.9% | −5.2% | −43.5% | 28.0% | 36.7% | 56.1% | 61.0% | −213.5% | 26.5% | 33.3% |
| Net margin | −29.8% | −39.2% | −81.5% | 5.0% | 27.3% | 127.7% | 42.6% | −226.4% | 0.2% | 8.1% |
| Free cash flow margin | −11.0% | −34.7% | −20.6% | 0.8% | 42.9% | 63.2% | 66.6% | 41.4% | 29.4% | 42.9% |
| Rule of 40 (growth + FCF margin) | 72.2% | −25.8% | −4.3% | 24.4% | 33.8% | 69.5% | 65.9% | 49.2% | 8.8% | 27.2% |
| Return on capital | — | — | — | — | — | 81.5% | 41.7% | −424.6% | — | — |
| Return on equity | −101.0% | −305.5% | — | — | — | 158.1% | 27.8% | −654.9% | — | — |
| Return on assets | −12.3% | −17.8% | −60.2% | 5.8% | 22.1% | 62.7% | 15.7% | −127.5% | 0.2% | 6.4% |
| Net debt to EBITDA | — | — | — | — | 0.5x | −0.7x | −1.0x | — | — | — |